Prevention of heart failure in the elderly

Česká verzia

Authors: Danzig Vilém
Authors place of work: Affidea Praha a II. interní klinika 1. LF UK VFN Praha
Published in the journal: Geriatrie a Gerontologie 2023, 12, č. 1: 23-26
Category: Review Article

Summary

Proper treatment of arterial hypertension can be considered as an essential primary prevention of heart failure in the elderly. Treatment of hypertension in the elderly is necessary for up to 80% of individuals, but it is not simple and has many specifics. It must be individualized and special attention must be paid to polypragmasia, drug interactions and the risk of orthostatic hypotension. Drug groups and target values do not differ substantially from the general population, but their achievement must be gradual and not always absolute. The determination of natriuretic peptide levels plays a crucial role in secondary prevention.

Keywords:

heart failure – natriuretic peptides – geriatric cardiology – pharmacotherapy of hypertension in seniors – ortostatic hypotension

Zdroje

1. Málek F, Veselý J, Pudil R, et al. Souhrn Doporučených postupů Evropské kardiologické společnosti pro diagnostiku a léčbu srdečního selhání z roku 2021. Cor Vasa 2022; 64: 121–162.

2. Špinar J, Hradec J, Špinarová L, et al. Summary of the 2016 ESC Guidelines on the diagnosis and treatment of acute and chronic heart failure. Prepared by the Czech Society of Cardiology. Cor Vasa 2016; 58: e530–568.

3. Lyon AR, López-Fernández T, Couch LS, et al. ESC Scientific Document Group, 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Euro Heart J 2022; 43(41): 4229–4361.

4. González-Colaço Harmand M, García-Sanz MDM, et al. Review on the management of cardiovascular risk factors in the elderly. J Geriatr Cardiol 2022; 19(11): 894–927.

5. Correa A, Rochlani Y, Khan MH, et al. Pharmacological management of hypertension in the elderly and frail populations. Expert Rev Clin Pharmacol 2018; 11(8): 805–817.

6. Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med; 358(18): 1887–1898.

7. Wang JG, Staessen JA. The benefit of treating isolated systolic hypertension. Curr Hypertens Rep 2001; 3(4): 333–339.

8. Widimsky J, Filipovský J, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze – verze 2022. Doporučení České společnosti pro hypertenzi. Hyper Kard Prevence 2022/2 Suppl.

9. Zazzara MB, Palmer K, Vetrano DL, et al. Adverse drug reactions in older adults: a narrative review of the literature. Eur Geriatr Med 2021; 12(3): 463–473.

10. Ricci F, De Caterina R, Fedorowski A. Orthostatic hypotension: epidemiology, prognosis, and treatment. J Am Coll Cardiol 2015; 66(7): 848–860.

11. Berlaimont V, Billiouw JM, Brohet C, et al. Lessons from ONTARGET. Acta Clin Belg 2008; 63(3): 142– 151.